 Infliximab
"Infliximab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A chimeric monoclonal antibody to TNF ALPHA that is used in the treatment of RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; PSORIATIC ARTHRITIS and CROHN'S DISEASE.
| Descriptor ID |
D000069285
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.608 D12.776.124.790.651.114.224.537 D12.776.377.715.548.114.224.642
|
| Concept/Terms |
Infliximab- Infliximab
- MAb cA2
- Monoclonal Antibody cA2
- Antibody cA2, Monoclonal
- cA2, Monoclonal Antibody
|
Below are MeSH descriptors whose meaning is more general than "Infliximab".
Below are MeSH descriptors whose meaning is more specific than "Infliximab".
This graph shows the total number of publications written about "Infliximab" by people in this website by year, and whether "Infliximab" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 2 | 2 | | 2013 | 0 | 1 | 1 | | 2019 | 1 | 0 | 1 | | 2021 | 1 | 0 | 1 | | 2023 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Infliximab" by people in Profiles.
-
Stewart S, Briggs KB, Dekonenko C, Fraser JA, Svetanoff WJ, Oyetunji TA, Bass JA, St Peter SD. Infliximab Rescue Therapy in Pediatric Severe Colitis. J Pediatr Surg. 2023 Oct; 58(10):1893-1897.
-
Burns JC, Roberts SC, Tremoulet AH, He F, Printz BF, Ashouri N, Jain SS, Michalik DE, Sharma K, Truong DT, Wood JB, Kim KK, Jain S. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child Adolesc Health. 2021 12; 5(12):852-861.
-
Chang HP, Shakhnovich V, Frymoyer A, Funk RS, Becker ML, Park KT, Shah DK. A population physiologically-based pharmacokinetic model to characterize antibody disposition in pediatrics and evaluation of the model using infliximab. Br J Clin Pharmacol. 2022 01; 88(1):290-302.
-
Funk RS, Shakhnovich V, Cho YK, Polireddy K, Jausurawong T, Gress K, Becker ML. Factors associated with reduced infliximab exposure in the treatment of pediatric autoimmune disorders: a cross-sectional prospective convenience sampling study. Pediatr Rheumatol Online J. 2021 May 01; 19(1):62.
-
Angeles-Han ST, Ringold S, Beukelman T, Lovell D, Cuello CA, Becker ML, Colbert RA, Feldman BM, Holland GN, Ferguson PJ, Gewanter H, Guzman J, Horonjeff J, Nigrovic PA, Ombrello MJ, Passo MH, Stoll ML, Rabinovich CE, Sen HN, Schneider R, Halyabar O, Hays K, Shah AA, Sullivan N, Szymanski AM, Turgunbaev M, Turner A, Reston J. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. Arthritis Rheumatol. 2019 06; 71(6):864-877.
-
Roberts SC, Jain S, Tremoulet AH, Kim KK, Burns JC, Anand V, Anderson M, Ang J, Ansusinha E, Arditi M, Ashouri N, Bartlett A, Chatterjee A, DeBiasi R, Dekker C, DeZure C, Didion L, Dominguez S, El Feghaly R, Erdem G, Halasa N, Harahsheh A, Jackson MA, Jaggi P, Jain S, Jone PN, Kaushik N, Kurio G, Lillian A, Lloyd D, Manaloor J, McNelis A, Michalik DE, Newburger J, Newcomer C, Perkins T, Portman M, Romero J, Ronis T, Rowley A, Schneider K, Schuster J, Tejtel SKS, Sharma K, Simonsen K, Szmuszkovicz J, Truong D, Wood J, Yeh S. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. Contemp Clin Trials. 2019 04; 79:98-103.
-
Turner D, Wolters VM, Russell RK, Shakhnovich V, Muise AM, Ledder O, Ngan B, Friesen C. Anti-TNF, infliximab, and adalimumab can be effective in eosinophilic bowel disease. J Pediatr Gastroenterol Nutr. 2013 May; 56(5):492-7.
-
Becker M, Ros? CD, McIlvain-Simpson G. Niacin-like reaction to infliximab infusion in systemic juvenile rheumatoid arthritis. J Rheumatol. 2004 Dec; 31(12):2529-30.
-
Friesen CA, Calabro C, Christenson K, Carpenter E, Welchert E, Daniel JF, Haslag S, Roberts CC. Safety of infliximab treatment in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2004 Sep; 39(3):265-9.
-
Carpenter E, Jackson MA, Friesen CA, Scarbrough M, Roberts CC. Crohn's-associated chronic recurrent multifocal osteomyelitis responsive to infliximab. J Pediatr. 2004 Apr; 144(4):541-4.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|